AlpInvest Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

AlpInvest Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-164,500	Closed	-$4.49M	–	15
2013 Q4	$4.49M	Sell	164,500 -378,901	-70%	-$9.18M	7.29%	4
2013 Q3	$12.5M	Hold	543,401	–	–	9.83%	4
2013 Q2	$9.62M	Buy	+543,401	New	+$10.6M	9.16%	5

Other funds holding ENTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

ICRM

Insight Capital Research & Management Walnut Creek, California $177M AUM 72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return

AlpInvest Partners's ENTA Position: Q1 2014 in Review

AlpInvest Partners sold out of Enanta Pharmaceuticals (ENTA) in Q1 2014, closing a stake of 164,500 shares — an estimated $4.49M sold.

AlpInvest Partners first reported a position in ENTA in Q2 2013 and held it in 3 quarters. The position peaked at $12.5M in Q3 2013. 81 funds tracked by Wall St. Rank hold ENTA as of Q1 2014.

AlpInvest Partners reported no remaining Enanta Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
AlpInvest Partners sold 164,500 Enanta Pharmaceuticals shares in Q1 2014, an estimated $4.49M.
AlpInvest Partners first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 3 quarters.
AlpInvest Partners's Enanta Pharmaceuticals position peaked at $12.5M in Q3 2013.
81 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2014.

Based on AlpInvest Partners's 13F filing for Q1 2014, filed 15 May 2014.